910 related articles for article (PubMed ID: 32905015)
1. Current approaches used in treating COVID-19 from a molecular mechanisms and immune response perspective.
Alnefaie A; Albogami S
Saudi Pharm J; 2020 Nov; 28(11):1333-1352. PubMed ID: 32905015
[TBL] [Abstract][Full Text] [Related]
2. Human and novel coronavirus infections in children: a review.
Rajapakse N; Dixit D
Paediatr Int Child Health; 2021 Feb; 41(1):36-55. PubMed ID: 32584199
[TBL] [Abstract][Full Text] [Related]
3. The origin, transmission and clinical therapies on coronavirus disease 2019 (COVID-19) outbreak - an update on the status.
Guo YR; Cao QD; Hong ZS; Tan YY; Chen SD; Jin HJ; Tan KS; Wang DY; Yan Y
Mil Med Res; 2020 Mar; 7(1):11. PubMed ID: 32169119
[TBL] [Abstract][Full Text] [Related]
4. Bioactive natural compounds against human coronaviruses: a review and perspective.
Xian Y; Zhang J; Bian Z; Zhou H; Zhang Z; Lin Z; Xu H
Acta Pharm Sin B; 2020 Jul; 10(7):1163-1174. PubMed ID: 32834947
[TBL] [Abstract][Full Text] [Related]
5. The outbreak of the novel severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2): A review of the current global status.
Bchetnia M; Girard C; Duchaine C; Laprise C
J Infect Public Health; 2020 Nov; 13(11):1601-1610. PubMed ID: 32778421
[TBL] [Abstract][Full Text] [Related]
6. Current Strategies of Antiviral Drug Discovery for COVID-19.
Mei M; Tan X
Front Mol Biosci; 2021; 8():671263. PubMed ID: 34055887
[TBL] [Abstract][Full Text] [Related]
7. Highlight of Immune Pathogenic Response and Hematopathologic Effect in SARS-CoV, MERS-CoV, and SARS-Cov-2 Infection.
Liang Y; Wang ML; Chien CS; Yarmishyn AA; Yang YP; Lai WY; Luo YH; Lin YT; Chen YJ; Chang PC; Chiou SH
Front Immunol; 2020; 11():1022. PubMed ID: 32574260
[TBL] [Abstract][Full Text] [Related]
8. Molecular mechanisms and epidemiology of COVID-19 from an allergist's perspective.
Hosoki K; Chakraborty A; Sur S
J Allergy Clin Immunol; 2020 Aug; 146(2):285-299. PubMed ID: 32624257
[TBL] [Abstract][Full Text] [Related]
9. Single domain antibodies derived from ancient animals as broadly neutralizing agents for SARS-CoV-2 and other coronaviruses.
Lim HT; Kok BH; Lim CP; Abdul Majeed AB; Leow CY; Leow CH
Biomed Eng Adv; 2022 Dec; 4():100054. PubMed ID: 36158162
[TBL] [Abstract][Full Text] [Related]
10. Epidemiology and Genomic Characterization of Two Novel SARS-Related Coronaviruses in Horseshoe Bats from Guangdong, China.
Li L; Zhang L; Zhou J; He X; Yu Y; Liu P; Huang W; Xiang Z; Chen J
mBio; 2022 Jun; 13(3):e0046322. PubMed ID: 35467426
[TBL] [Abstract][Full Text] [Related]
11. SARS-Cov2 acute and post-active infection in the context of autoimmune and chronic inflammatory diseases.
Larionova R; Byvaltsev K; Kravtsova О; Takha E; Petrov S; Kazarian G; Valeeva A; Shuralev E; Mukminov M; Renaudineau Y; Arleevskaya M
J Transl Autoimmun; 2022; 5():100154. PubMed ID: 35434592
[TBL] [Abstract][Full Text] [Related]
12. Therapeutic approaches and vaccination in fighting COVID-19 infections: A review.
Adibzadeh S; Amiri S; Nia GE; Taleghani MR; Bijarpas ZK; Maserat N; Maali A; Azad M; Behzad-Behbahani A
Gene Rep; 2022 Jun; 27():101619. PubMed ID: 35530725
[TBL] [Abstract][Full Text] [Related]
13. Emergence, evolution, and vaccine production approaches of SARS-CoV-2 virus: Benefits of getting vaccinated and common questions.
Hassanin AA; Haidar Abbas Raza S; Ahmed Ujjan J; Aysh ALrashidi A; Sitohy BM; Al-Surhanee AA; Saad AM; Mohamed Al-Hazani T; Osman Atallah O; Al Syaad KM; Ezzat Ahmed A; Swelum AA; El-Saadony MT; Sitohy MZ
Saudi J Biol Sci; 2022 Apr; 29(4):1981-1997. PubMed ID: 34924802
[TBL] [Abstract][Full Text] [Related]
14. Biological, clinical and epidemiological features of COVID-19, SARS and MERS and AutoDock simulation of ACE2.
Zhang XY; Huang HJ; Zhuang DL; Nasser MI; Yang MH; Zhu P; Zhao MY
Infect Dis Poverty; 2020 Jul; 9(1):99. PubMed ID: 32690096
[TBL] [Abstract][Full Text] [Related]
15. Insights into forsythia honeysuckle (Lianhuaqingwen) capsules: A Chinese herbal medicine repurposed for COVID-19 pandemic.
Liang C; Hui N; Liu Y; Qiao G; Li J; Tian L; Ju X; Jia M; Liu H; Cao W; Yu P; Li H; Ren X
Phytomed Plus; 2021 May; 1(2):100027. PubMed ID: 35399819
[TBL] [Abstract][Full Text] [Related]
16. Testing the efficacy and safety of BIO101, for the prevention of respiratory deterioration, in patients with COVID-19 pneumonia (COVA study): a structured summary of a study protocol for a randomised controlled trial.
Dioh W; Chabane M; Tourette C; Azbekyan A; Morelot-Panzini C; Hajjar LA; Lins M; Nair GB; Whitehouse T; Mariani J; Latil M; Camelo S; Lafont R; Dilda PJ; Veillet S; Agus S
Trials; 2021 Jan; 22(1):42. PubMed ID: 33430924
[TBL] [Abstract][Full Text] [Related]
17. Disruption of CCR5 signaling to treat COVID-19-associated cytokine storm: Case series of four critically ill patients treated with leronlimab.
Agresti N; Lalezari JP; Amodeo PP; Mody K; Mosher SF; Seethamraju H; Kelly SA; Pourhassan NZ; Sudduth CD; Bovinet C; ElSharkawi AE; Patterson BK; Stephen R; Sacha JB; Wu HL; Gross SA; Dhody K
J Transl Autoimmun; 2021; 4():100083. PubMed ID: 33521616
[TBL] [Abstract][Full Text] [Related]
18. Zoonotic origins of human coronaviruses.
Ye ZW; Yuan S; Yuen KS; Fung SY; Chan CP; Jin DY
Int J Biol Sci; 2020; 16(10):1686-1697. PubMed ID: 32226286
[TBL] [Abstract][Full Text] [Related]
19. The TMPRSS2 Inhibitor Nafamostat Reduces SARS-CoV-2 Pulmonary Infection in Mouse Models of COVID-19.
Li K; Meyerholz DK; Bartlett JA; McCray PB
mBio; 2021 Aug; 12(4):e0097021. PubMed ID: 34340553
[TBL] [Abstract][Full Text] [Related]
20. Current status of antivirals and druggable targets of SARS CoV-2 and other human pathogenic coronaviruses.
Artese A; Svicher V; Costa G; Salpini R; Di Maio VC; Alkhatib M; Ambrosio FA; Santoro MM; Assaraf YG; Alcaro S; Ceccherini-Silberstein F
Drug Resist Updat; 2020 Dec; 53():100721. PubMed ID: 33132205
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
